文献速递浆细胞疾病

多发性骨髓瘤循环肿瘤细胞是骨髓高危基因组改变与肿瘤负荷的复合生物标志物

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.
PubMed 文献 · Blood · 2026-01-01

本研究对新诊断多发性骨髓瘤患者的配对骨髓和血液样本进行单细胞转录组和全基因组测序,发现CTC与骨髓细胞转录相似,无独特循环亚群。高CTC患者骨髓瘤细胞增殖增加且原发遗传事件不平衡,CTC水平依赖原发和继发高危基因组事件及肿瘤负荷,并建立预测模型。

要点

  • 高CTC水平提示骨髓瘤细胞增殖活跃及高危基因组改变。
  • CTC水平由肿瘤负荷、原发易位和继发基因组事件共同决定。
  • CTC可作为新诊断骨髓瘤基因组驱动高危疾病的生物标志物。

核心结论

  • CTC是肿瘤负荷、原发易位和继发基因组事件的净结果,可作为新诊断骨髓瘤基因组驱动高危疾病的强效生物标志物。

研究设计与样本

  • 研究分析新诊断多发性骨髓瘤患者的配对骨髓和血液样本,采用单细胞转录组和全基因组测序,并利用CoMMpass数据集进行全外显子和批量RNA测序分析及内部数据验证。

主要发现

  • CTC与配对骨髓细胞在单个克隆水平转录相似,无独特循环群体证据。
  • 高CTC患者骨髓瘤细胞增殖增加且原发遗传事件不平衡,包括MAF和CCND易位富集。
  • 高CTC患者骨髓瘤细胞一致表现为增殖转录特征。
  • CTC水平独特依赖原发基因组事件和高危继发事件,如amp1q、del1p、del13q、双等位TP53突变及APOBEC突变增加,即使无MAF易位。

临床怎么用

  • CTC水平可用于识别新诊断骨髓瘤中基因组驱动的高危患者,辅助风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High levels of circulating tumor cells (CTC) are a powerful predictor of poor outcomes in newly diagnosed multiple myeloma, yet the mechanistic underpinnings of this correlation remain unknown. To investigate whether CTC-related pathobiology is driven by a specific CTC subset, paired bone marrow and blood samples from patients with newly diagnosed multiple myeloma were analyzed by single-cell transcriptomics and whole-genome sequencing. This revealed that down to the individual clone level, CTC and paired bone marrow cells are transcriptionally similar, without evidence for a distinct circulating population. In contrast, bone marrow myeloma cells from patients with high CTC levels had increased proliferation and unbalanced primary genetic events, including enrichment for MAF and CCND translocations. To investigate the impact of heterogenic genomic events on CTC levels, whole-exome and bulk RNA sequencing from the Multiple Myeloma Research Foundation CoMMpass data set were analyzed and validated in our in-house data sets. Bone marrow tumor cells from patients with high CTC levels were uniformly characterized by transcriptomic signatures of proliferation. Furthermore, CTC levels were uniquely dependent on primary genomic events and high-risk secondary genomic events, including amplification 1q, deletion 1p, deletion 13q, biallelic TP53 mutations, and increased apolipoprotein B editing complex-induced mutations even in patients without MAF translocations. Finally, we developed a model that predicts the impact of genetic alterations and tumor burden on CTC levels. In sum, we reveal that CTC are the net result of tumor burden, primary translocations, and secondary genomic events, making CTC a powerful biomarker for genomics-driven high-risk disease in patients with newly diagnosed myeloma.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Fokkema C, Bertamini L, de Jong MME, et al. Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load. Blood. 2026. PMID: 41411148. doi:10.1182/blood.2025030083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。